GeneNews Sees Uptick in Q3 Revenues; Cuts Net Loss by 64 Percent

The Canadian biomarker test developer attributed the revenue increase to a collaborative research agreement; an Asian biomedical consortium; and sales of its ColonSentry biomarker test.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories